Bitcoin price today: rises to $116.5k on Trump 401k order, altcoins rally
Haleon plc (LSE/NYSE:HLN), a global leader in consumer health, reported on Wednesday that several Persons Discharging Managerial Responsibilities (PDMRs) have recently engaged in transactions involving the company’s shares. The transactions, which took place on June 9 and June 10, 2025, were carried out on the London Stock Exchange (LON:LSEG) and involved the acquisition of ordinary shares as a result of dividend reinvestment. Additionally, some PDMRs acquired partnership shares and were awarded matching shares under the company’s Share Reward Plan.
The transactions were reported in accordance with the UK Market Abuse Regulation, which mandates public disclosure of such activities by insiders. The specific details of the transactions, including the names of the PDMRs, the nature of the transactions, prices, volumes, and the dates on which the transactions took place, have been officially recorded and filed.
Haleon’s portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren. The company is committed to delivering better everyday health with humanity, leveraging trusted science, innovation, and a deep understanding of consumer needs.
For further information, Haleon directs interested parties to its website. The company’s actions are governed by the requirements of the Securities Exchange Act of 1934, and the report was duly signed by the authorized company secretary, Amanda Mellor. The filing provides transparency into the dealings of company insiders, offering investors and the public insight into the actions of Haleon’s management team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.